The tumor-suppressive role of TCPTP in T-ALLs is attributed to its capacity to attenuate oncogenic protein tyrosine kinase signalling, including that mediated by JAK1 [46], and the aberrant fusion protein NUP214-ABL1 [45]. Here, ABL1 is linked to neoplasm.